Results 231 to 240 of about 4,166,507 (358)

Inhibitors of Proteases: A Well-Grounded Strategy in Drug Development. [PDF]

Molecules
Previti S, Ettari R.
europepmc   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Characterizing epithelial‐mesenchymal transition‐linked heterogeneity in breast cancer circulating tumor cells at a single‐cell level

Molecular Oncology, EarlyView.
In over 50% of non‐metastatic breast cancer patients, circulating tumor cells (CTCs) along the whole epithelial‐mesenchymal transition spectrum are detected. Total CTC number and individual phenotypes relate to aggressive disease characteristics, including lymph node involvement and higher tumor proliferation. At the single‐cell level, mesenchymal CTCs
Justyna Topa, Julia Richert, Tomasz Stokowy, Alicja Staśczak, Mariusz Szajewski, Maciej Ciesielski, Petra M. Grešner, Bartłomiej Tomasik, Łukasz Arcimowicz, Agnieszka Stankiewicz, Grażyna Suchodolska, Elżbieta Senkus, Wiesław Kruszewski, Anna J. Żaczek, Aleksandra Markiewicz   +14 more
wiley   +1 more source

Monoclonal Antibodies: Historical Perspective and Current Trends in Biological Drug Development. [PDF]

Int J Mol Sci
Madej B, Tomaszewski F, Szmajda-Krygier D, Świechowski R, Jeleń A, Mirowski M.   +5 more
europepmc   +1 more source

Comparative studies of drug effects and mechanisms of development of ventricular tachycardia based on precise analyses of the incidence of ventricular extrasystole.

, 1988
Yoshio Onishi
openalex   +2 more sources

The IFNγ‐CIITA‐MHC II axis modulates melanoma cell susceptibility to NK‐cell‐mediated cytotoxicity

Molecular Oncology, EarlyView.
Natural killer (NK) cells play a central role in anti‐melanoma immunity. However, melanoma cells adapt during co‐culture by upregulating CIITA and MHC II in response to interferon gamma (IFNγ), thereby evading NK‐cell lysis. Blocking IFNγ signaling or treatment with dimethyl fumarate/simvastatin counteracts this immune escape and maintains NK‐cell ...
Lena C. M. Krause, Rixa‐Mareike Köhn, Christian Ickes, Julia Lenger, Jonas Fischer, Sabrina Cappello, Ivan Bogeski   +6 more
wiley   +1 more source

Scientific and regulatory progress in advancing paediatric oncology drug development in the EU and in the US. [PDF]

Front Med (Lausanne)
Reggiardo G, Natale A, Santoro N, Giannuzzi V, Pansieri C, Felisi M, Bonifazi D, Ceci A.   +7 more
europepmc   +1 more source

Relationship between tension development and ATP hydrolysis by skinned skeletal muscle fibers and its modification by drugs

, 1989
Nagomi Kurebayashi, Yasuo Ogawa
openalex   +1 more source

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

Financing drug development via adaptive platform trials. [PDF]

PLoS One
Cho J, Sorets E, Chaudhuri S, De Mattos A, Drake K, Cudkowicz ME, Ortiz R, Hasenoehrl M, Chase M, Harkey B, Paganoni S, Frishkopf J, Lo AW.   +12 more
europepmc   +1 more source